Abstract

Doc number: 247

Abstract

Background: The purpose of our study was to prospectively report the clinical results of 280 consecutive hips (240 patients) who received a ReCap Hip Resurfacing System implant (Biomet Inc., Warsaw, USA) in a single district general hospital. Literature reports a large variation in clinical results between different resurfacing designs and published results using this particular design are scarce.

Methods: Mean follow up was 3.3 years (1.0 to 6.3) and four patients were lost to follow-up. All patients were diagnosed with end-stage hip osteoarthritis, their mean age was 54 years and 76.4% of all patients were male.

Results: There were 16 revisions and four patients reported a Harris Hip Score <70 points at their latest follow up. There were no pending revisions. Kaplan-Meier implant survival probability, with revision for any reason as endpoint, was 93.5% at six years follow-up (95%-CI: 88.8-95.3). There were no revisions for Adverse Reactions to Metal Debris (ARMD) and no indications of ARMD in symptomatic non-revised patients, although diagnostics were limited to ultrasound scans.

Conclusions: This independent series confirms that hip resurfacing is a demanding procedure, and that implant survival of the ReCap hip resurfacing system is on a critical level in our series. In non-revised patients, reported outcomes are generally excellent.

Trial registration: ClinicalTrials.gov Identifier: NCT00603395

Details

Title
Hip resurfacing in a district general hospital: 6-year clinical results using the ReCap hip resurfacing system
Author
van der Weegen, Walter; Hoekstra, Henk J; Sijbesma, Thea; Austen, Shennah; Poolman, Rudolf W
Pages
247
Publication year
2012
Publication date
2012
Publisher
BioMed Central
e-ISSN
14712474
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1242248582
Copyright
© 2012 van der Weegen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.